Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entasis Therapeutics Holdings Inc.

www.entasistx.com

Latest From Entasis Therapeutics Holdings Inc.

German Government Joins Superbug Fight With €40m CARB-X Investment

Germany’s Ministry of Education and Research has pledged €40m over four years to the antibacterial accelerator CARB-X, part of an overall €500m the country has committed to fighting superbugs in the next decade.

Infectious Diseases Germany

Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts

Melinta describes difficulties launching its new antibiotics at BIO CEO & Investor Conference; companies and other stakeholders urge Congress to enact package of incentives to reinvigorate antibiotic pipeline.

Infectious Diseases Commercial

Commercial, Reimbursement Hurdles Need To Be Addressed By Antimicrobial Resistance Efforts

Melinta describes difficulties launching its new antibiotics at BIO CEO & Investor Conference; companies and other stakeholders urge Congress to enact package of incentives to reinvigorate antibiotic pipeline.

Infectious Diseases Reimbursement

Finance Watch: Bitcoin For Biopharma? Agenus Gives BEST A Shot

Investors in a February Biotech Electronic Security Token (BEST) offering will be able to put their money behind a single Agenus asset – the PD-1 inhibitor AGEN2034. Also, financial and strategic updates from Gossamer, Aduro, Novo's REPAIR Impact Fund and more.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Entasis Therapeutics
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Entasis Therapeutics Holdings Inc.
  • Senior Management
  • Manos Perros, Pres. & CEO
    Mike Gutch, PhD, CBO & CFO
    Robin Isaacs, MD, CMO
    Ruben Tommasi, PhD, CSO
    Eric Kimble, Chief Commercial Officer
  • Contact Info
  • Entasis Therapeutics Holdings Inc.
    35 Gatehouse Dr.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register